IVD Registration Path and Analytical Performance Evidence in Iran

1. Key takeaways

In vitro diagnostic reagents (IVDs) in Iran are likewise organised under the four-class risk framework of A, B, C and D, but the classification logic shifts from the degree of device invasiveness toward the human body to the impact of an incorrect test result on patients and public health. The judgment of GRZAN is that the common rejection point for IVD projects lies not in the classification itself but in the separation of analytical performance evidence from clinical performance evidence — companies frequently submit large volumes of clinical data while lacking systematic evidence of analytical performance: precision, accuracy, limit of detection and interference. The reviewer is therefore left with clinical conclusions that no analytical backbone supports, and the dossier is returned for supplementation. Closing this gap is not a matter of adding more clinical studies but of adding the analytical modules that the IVD evidence architecture specifically expects. The result is that the six analytical modules function as a pass/fail gate for the whole dossier, not as supporting material.

• Iran organises review depth according to the A/B/C/D four-class framework, with classification based on the manufacturer’s intended use and field of application.
• The complete application file uses the UMDNS nomenclature system, as recorded in the WHO overview of medical device nomenclature systems for Iran.
• The six core analytical performance modules are precision, accuracy, limit of detection, linear range, interference and cross-reaction, and stability.
• Analytical performance evidence must be organised as a separate volume and not mixed together with clinical performance data.
• Reagents described as intended for screening, blood typing or critical-care decisions will attract a higher risk class than routine biochemistry reagents.
• Shelf life and transport conditions directly affect result reliability, and Iran’s high-temperature environment raises the weight of transport verification relative to device products.
• UMDNS coding must be mapped for every product configuration, because IVD portfolios typically contain many individual items.
• Classification consequences follow claim language, so the intended use wording should be drafted with the risk class deliberately in view.

2. Legal basis

On the risk classification framework: Iran organises review depth according to the four classes A/B/C/D, and classification is based on the intended use and field of application declared by the manufacturer. This means the claim language in the application directly drives the class assigned, which is why wording choices carry classification consequences. This is documented in public industry database records; the official document number has not been released through public channels, and this is a practical estimate.

On nomenclature: the complete application file uses the UMDNS nomenclature system. This is recorded in the entry for Iran in the World Health Organization overview of medical device nomenclature systems in WHO Member States, which makes UMDNS coding a structural requirement of the dossier rather than an optional convenience.

The statutory anchor remains the Law Concerning Regulations of Medical, Laboratory, Pharmaceutical and Food and Beverage Affairs, recorded in FAOLEX as LEX-FAOC227692, dated 1955-06-20, Article 3.

3. Expert insights

Insight 1: the risk of an IVD derives from the consequences of a wrong result. Reagents used for infectious disease screening, blood type identification or critical-care decisions carry a markedly higher risk class than routine biochemistry reagents. Companies should be aware when drafting their intended use claims that describing a reagent as serving screening purposes will raise the risk class, and that the claim language therefore needs to be chosen with the classification consequence consciously in view. The same reagent can often be described accurately at a narrower scope, and that narrower description may keep the project in a lower review tier without misstating the product.

Insight 2: analytical performance evidence is the skeleton of the IVD dossier. Precision, accuracy, limit of detection, linear range, interference and cross-reaction, and stability are evidence modules specific to IVDs. GRZAN requires IVD projects to submit analytical performance as a separate volume, not interleaved with clinical performance, so that the reviewer can verify the six core modules in one place and confirm that the analytical backbone of the case is complete before turning to the clinical layer. A reviewer who can trace each of the six modules in one place processes the dossier faster, and speed in the review channel is precisely what the evidence architecture is designed to buy.

Insight 3: cold chain and stability are especially critical for IVDs. The shelf life and the transport conditions of reagents directly affect the reliability of results. Iran’s high-temperature environment raises the importance of transport verification, and this factor carries greater weight for IVDs than for device products, where transport conditions rarely influence diagnostic performance in the same direct way. A transport verification protocol designed for temperate climates will simply not answer the question the Iranian reviewer is asking.

4. Practical recommendations

• Submit analytical performance as a separate volume: consolidate precision, accuracy, limit of detection, interference and the other core modules in one place, without mixing them into the clinical data, so the reviewer meets the analytical backbone before the clinical layer.
• Phrase claims with caution: avoid expanding the described use of a reagent into screening, so as not to raise the risk class unnecessarily.
• Front-load stability and transport verification: design the transport verification protocol specifically for Iran’s high-temperature environment.
• Complete UMDNS coding mapping item by item: IVD product configurations are numerous, so the coding mapping must be completed for every single item.

5. Verification checklist

• □ The A/B/C/D classification determination has been completed and the reasons recorded in writing
• □ Analytical performance evidence has been organised as a separate volume with all 6 core indicators complete
• □ Clinical performance evidence and analytical performance evidence have been organised separately
• □ Stability and high-temperature transport verification have been completed
• □ UMDNS coding mapping has been completed for every product configuration

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages IFDA registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com